- Company
- Kynteles is added in the revision of the domestic guidelines
- by Eo, Yun-Ho Aug 13, 2020 06:25am
- Kynteles is expected to be recommended as the first line therapy in the domestic IBD guidelines. Kim Joo-sung, president of the KASID( Department of Gastroenterology, SNUH), guided domestically at a press conference to commemorate the expansion of insurance coverage for the first-line treatment of Inflammatory Bowel Disease (IBD) of Takeda
- Company
- Quadrivalent Flu Vaccine for NIP, failed in bidding
- by Aug 13, 2020 06:25am
- The procurement of a tetravalent vaccine for influenza for NIP failed bidding three times due to an excessively low unit price. According to related industries on the 10th, two bids for the '2020-2021 season influenza vaccine purchase' conducted by the KCDC were failed on the 28th of last month. Initially, New Medipharm and PharmWorld (NIP
- Company
- Big 5 pass Qsymia powered by Alvogen-CKD co-marketing
- by Eo, Yun-Ho Aug 12, 2020 06:00am
- The Big Five general hospitals have cleared the prescription of Qsymia speedily widening its brand awareness within the obesity treatment market. According to pharmaceutical industry sources, the drug committees at Big Five hospitals like Seoul National University Hospital, Severance Hospital, Samsung Seoul Medical Center and Seoul Asan
- Company
- Sayana and Gonal-F shortage may last longer than expected
- by Aug 12, 2020 05:59am
- Shortages in various drug products are reportedly caused by manufacturing facility changes and unstable supply of pharmaceutical substances. According to pharmaceutical distribution industry sources on Aug. 10, Pfizer Pharmaceutical Korea, Merck Korea, Dalim Biotech and other companies have recently informed of shortages in some products
- Company
- Appropriate use of NOAC in patient with major bleeding risk
- by Eo, Yun-Ho Aug 10, 2020 06:02am
- As the prescription cases of new oral anti-coagulant (NOAC) have been accumulating, the prescribers are paying a closer attention on adequately prescribing for patients with high risk of bleeding. HAS-BLED score, the most well known scoring system for measuring major bleeding risk, indicates patients scoring over three are equivalent to
- Company
- Hanmi, promotes COVID-19 tx, Ambroxol HCl Sln for Inhalation
- by Aug 10, 2020 06:00am
- Hanmi's Chinese subsidiary, Beijing Hanmi Pharmaceutical, announced on the 6th that it will develop a secretolytic agent, 'Ambroxol HCl Solution for Inhalation' as COVID-19 treatment. Earlier, top expert consensus in Chinese pediatrics and two organizations at the drug management control center in Guangdong Province, China, commented on
- Company
- AZ, Takeda and Pfizer to compete in PARP inhibitor market
- by Eo, Yun-Ho Aug 7, 2020 06:28am
- The competition ground among poly ADP ribose polymerase (PARP) inhibitors targeting BRCA gene has widened as Pfizer entered the South Korean market following the footsteps of AstraZeneca and Takeda Pharmaceutical. According to the pharmaceutical industry sources, the Korean health authority approved of Pfizer Korea’s Talzenna (talazopa
- Company
- A big deal after various exchanges between companies
- by Lee, Seok-Jun Aug 7, 2020 06:27am
- Big Deal (License Out/LO) of the traditional pharmaceutical companies show that there have been various exchanges in the past. Looking at the recently established Hanmi and Yuhan’s technology transfer partners, it was because there were exchanges such as joint promotion in the past. It was that exchanges in the past led to exchanges between
- Company
- SGLT-2 inhibitors growth surge by 30% in antidiabetic market
- by An, Kyung-Jin Aug 7, 2020 06:26am
- In the South Korean oral antidiabetic drug market, the influence of sodium-glucose cotransporter-2 (SGLT2) inhibitors has expanded even further. The outpatient prescription sales in the medicine broke through the 50-million-won point as the single drug prescription is constantly growing and combination therapies have been effective. AstraZ
- Company
- Hanmi signed a technology transfer of ₩1 trillion
- by Lee, Seok-Jun Aug 7, 2020 06:26am
- Hanmi signed a technology transfer agreement of &8361;1 trillion ($860 million). The down payment is $10 million (&8361;12 billion), and the other side is MSD, a global US pharmaceutical company. Hanmi announced on the 4th that it has signed a license agreement with MSD to develop, manufacture and commercialize the biomedicine candidate
